Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

VEGF Receptor Inhibitor-Induced Hypertension: Emerging Mechanisms and Clinical Implications
Nicholas D. Camarda, Richard Travers, Vicky K. Yang, et al.
Current Oncology Reports (2022) Vol. 24, Iss. 4, pp. 463-474
Open Access | Times Cited: 51

Showing 1-25 of 51 citing articles:

Cancer Therapy–Related Hypertension: A Scientific Statement From the American Heart Association
Jordana B. Cohen, Nancy J. Brown, Sherry‐Ann Brown, et al.
Hypertension (2023) Vol. 80, Iss. 3
Open Access | Times Cited: 88
Smooth Muscle Mineralocorticoid Receptor Promotes Hypertension After Preeclampsia
Lauren A. Biwer, Qing Lu, Jaime Ibarrola, et al.
Circulation Research (2023) Vol. 132, Iss. 6, pp. 674-689
Open Access | Times Cited: 21
VEGF (Vascular Endothelial Growth Factor) Inhibition and Hypertension: Does Microvascular Rarefaction Play a Role?
F.A.C. le Noble, Jean‐Jacques Mourad, Bernard Lévy, et al.
Hypertension (2023) Vol. 80, Iss. 5, pp. 901-911
Closed Access | Times Cited: 17
Alterations in endothelial nitric oxide synthase activity and their relevance to blood pressure
Tatsiana Suvorava, Sara Metry, Stephanie Pick, et al.
Biochemical Pharmacology (2022) Vol. 205, pp. 115256-115256
Closed Access | Times Cited: 27
New advances in the research of clinical treatment and novel anticancer agents in tumor angiogenesis
Xin Li, Jianbo Zhou, Xue Wang, et al.
Biomedicine & Pharmacotherapy (2023) Vol. 163, pp. 114806-114806
Open Access | Times Cited: 16
Management of metastatic pheochromocytomas and paragangliomas: when and what
Vineeth Sukrithan, Kimberly Perez, Neeta Pandit‐Taskar, et al.
Current Problems in Cancer (2024) Vol. 51, pp. 101116-101116
Open Access | Times Cited: 5
Inhibition of YAP by lenvatinib in endothelial cells increases blood pressure through ferroptosis
Liang Chen, Di Zhu, Wei Xia, et al.
Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease (2022) Vol. 1869, Iss. 1, pp. 166586-166586
Open Access | Times Cited: 19
Established and Emerging Cancer Therapies and Cardiovascular System: Focus on Hypertension—Mechanisms and Mitigation
Lloyd Butel-Simoes, Tatt Jhong Haw, Trent Williams, et al.
Hypertension (2023) Vol. 80, Iss. 4, pp. 685-710
Open Access | Times Cited: 11
Effect of Intensive Blood Pressure Control on Cardiovascular Outcomes in Cancer Survivors
Wenjie Li, Zhiyan Wang, Chao Jiang, et al.
Hypertension (2024) Vol. 81, Iss. 3, pp. 620-628
Closed Access | Times Cited: 4
Endothelin receptor antagonists (ERAs) can potentially be used as therapeutic drugs to reduce hypertension caused by small molecule tyrosine kinase inhibitors (TKIs)
Qingjian He, Junling Lin, Chaohua Mo, et al.
Frontiers in Pharmacology (2025) Vol. 15
Open Access
Acute vascular and cardiac effects of lenvatinib in mice
Dustin N. Krüger, Patrizia Pannucci, Callan D. Wesley, et al.
Cardio-Oncology (2025) Vol. 11, Iss. 1
Open Access
Is lenvatinib-induced blood pressure elevation a favorable prognostic factor in patients with hepatocellular carcinoma?
Satoshi Kidoguchi
Hypertension Research (2025)
Closed Access
Safety assessment of ripretinib: a real-world adverse event analysis from the food and drug administration adverse event reporting system
Shijia Wang, H. Chen, Yuying Zhou, et al.
Frontiers in Oncology (2025) Vol. 15
Open Access
Potential role of endothelial dysfunction in hypertension and proteinuria in patients with hepatocellular carcinoma receiving atezolizumab plus bevacizumab: a pilot prospective observational study
Satoru Nihei, Kazuki Saito, Tatsuki Ikeda, et al.
Cancer Chemotherapy and Pharmacology (2025) Vol. 95, Iss. 1
Closed Access
Management of hypertension in patients with cancer: challenges and considerations
Shubhi Pandey, Amar Kalaria, Kenar D. Jhaveri, et al.
Clinical Kidney Journal (2023) Vol. 16, Iss. 12, pp. 2336-2348
Open Access | Times Cited: 9
How to deal with renal toxicities from immune-based combination treatments in metastatic renal cell carcinoma. A nephrological consultation for Oncologists
Marcello Tucci, Laura Cosmai, Marta Pirovano, et al.
Cancer Treatment Reviews (2024) Vol. 125, pp. 102692-102692
Closed Access | Times Cited: 3
Hypertension associated with niraparib in cancer patients: A pharmacovigilance analysis based on the FAERS database and meta-analysis of randomized controlled trials
Wei Chen, Jiyi Xie, Chen Gao, et al.
Gynecologic Oncology (2024) Vol. 182, pp. 108-114
Closed Access | Times Cited: 3
Receptor Tyrosine Kinase: Still an Interesting Target to Inhibit the Proliferation of Vascular Smooth Muscle Cells
Yilin Xiong, Yan Wang, Tao Yang, et al.
American Journal of Cardiovascular Drugs (2023) Vol. 23, Iss. 5, pp. 497-518
Closed Access | Times Cited: 7
Metabolism, toxicity and management of fruquintinib: a novel drug for metastatic colorectal cancer
Kanchi Patell, Veronica Mears, Michael H. Storandt, et al.
Expert Opinion on Drug Metabolism & Toxicology (2024) Vol. 20, Iss. 4, pp. 197-205
Closed Access | Times Cited: 2
Identifying mitigating strategies for endothelial cell dysfunction and hypertension in response to VEGF receptor inhibitors
Nicholas D. Camarda, Qing Lu, Dawn M. Meola, et al.
Clinical Science (2024) Vol. 138, Iss. 18, pp. 1131-1150
Closed Access | Times Cited: 2
The biased apelin receptor agonist, MM07, reverses Sugen/hypoxia-induced pulmonary arterial hypertension as effectively as the endothelin antagonist macitentan
Thomas Williams, Duuamene Nyimanu, Rhoda E. Kuc, et al.
Frontiers in Pharmacology (2024) Vol. 15
Open Access | Times Cited: 2
Cardiorenal Impact of Anti-Cancer Agents: The Intersection of Onco-Nephrology and Cardio-Oncology
Rose Mary Attieh, Belen Nunez, Robert S Copeland-Halperin, et al.
Cardiorenal Medicine (2024), pp. 1-1
Open Access | Times Cited: 2
Cardiovascular Complications of Pan-Cancer Therapies: The Need for Cardio-Oncology
Mengjia Chen, Jianing Xue, Maoling Wang, et al.
Cancers (2023) Vol. 15, Iss. 11, pp. 3055-3055
Open Access | Times Cited: 6
Role of endothelin ETA receptors in the hypertension induced by the VEGFR-2 kinase inhibitors axitinib and lenvatinib in conscious freely-moving rats
Patrizia Pannucci, Marieke Van Daele, Samantha Cooper, et al.
Biochemical Pharmacology (2023) Vol. 228, pp. 116007-116007
Open Access | Times Cited: 5
Evaluation of Apatinib-Related Hypertension and Identification of Clinical Risk Factors
Kaidi Le, Min Liu, Yinglin Ma, et al.
Journal of Clinical Pharmacy and Therapeutics (2024) Vol. 2024, pp. 1-8
Open Access | Times Cited: 1
Page 1 - Next Page

Scroll to top